Related Experiment Videos
Prolactin secretion and menstrual function after long-term bromocriptine treatment.
1Department of Obstetrics and Gynecology, Uppsala University, Sweden.
Fertility and Sterility
|October 1, 1987
Summary
Long-term bromocriptine treatment can lead to sustained normalization of prolactin levels in women with hyperprolactinemia. Many women maintained normal prolactin and menstrual function even after discontinuing the medication.
Area of Science:
- Endocrinology
- Reproductive Medicine
Background:
- Hyperprolactinemia is a condition characterized by elevated prolactin levels.
- Bromocriptine is a dopamine agonist commonly used to treat hyperprolactinemia.
Purpose of the Study:
- To evaluate the long-term effects of discontinuing bromocriptine treatment in hyperprolactinemic women.
- To assess the durability of prolactin level normalization and menstrual function after bromocriptine withdrawal.
Main Methods:
- Observational study following 75 hyperprolactinemic women after long-term bromocriptine treatment discontinuation.
- Monitoring of prolactin levels and menstrual bleeding patterns in women who stopped treatment.
- Analysis of treatment reinstitution in a subset of patients.
Main Results:
- 56% of women required reinstitution of bromocriptine due to rising prolactin levels.
- 44% of women were followed for >= 6 months without treatment; 58% experienced menstrual bleeding.
- Mean prolactin levels decreased by over 60% in women off treatment, indicating sustained normalization.
Conclusions:
- Long-term bromocriptine therapy appears to induce long-standing normalization of prolactin secretion.
- A significant proportion of hyperprolactinemic women may maintain normalized prolactin levels and menstrual function after treatment cessation.